N-Pentyl-L-histidine | 58813-22-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Pentyl-L-histidine
• 英文别名: (2S)-3-(1H-imidazol-5-yl)-2-(pentylamino)propanoic acid
• CAS: 58813-22-2
• 化学式: C₁₁H₁₉N₃O₂
• 分子量: 225.29
• InChiKey: RLIFGJIMCMUZJE-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  78
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Surface modification using N-acyl lysines
  申请人：AJINOMOTO CO., INC.

  公开号：EP0139481A2

  公开（公告）日：1985-05-02

  There is disclosed a formulation comprising a base component in combination with one or more organic component chosen from N-mono- and N,N-di-acylated basic amino acids, wherein the acyl group in the N-mono-acylated basic amino acid is an aliphatic acyl group having from 8 to 22 carbon atoms, and each of the acyl groups, which may be the same or different, in the N,N-di-acylated basic amino acid is an aliphatic acyl group having from 1 to 22 carbon atoms with the proviso that the two aliphatic acyl groups together have from 9 to 44 carbon atoms. The formulation is useful in novel cosmetics and as a novel surface-modified inorganic filler.

  本发明公开了一种制剂，该制剂由基质成分与一种或多种选自 N-单-和 N,N-二-酰化碱性氨基酸的有机成分组合而成，其中 N-单-酰化碱性氨基酸中的酰基是具有 8 至 22 个碳原子的脂肪族酰基、N,N-二乙酰化碱性氨基酸中的每个酰基（可以相同或不同）都是具有 1 至 22 个碳原子的脂肪族酰基，但这两个脂肪族酰基加在一起具有 9 至 44 个碳原子。 该配方可用于新型化妆品和新型表面改性无机填料。
• Compositions and methods for treating diseases by inhibiting exosome release
  申请人：MOREHOUSE SCHOOL OF MEDICINE

  公开号：US10040831B2

  公开（公告）日：2018-08-07

  A multipartite peptide that inhibits release of exosomes in a cell, comprising an N-terminal end and a C-terminal end and comprising at least one secretion modifying region (SMR) peptide from HIV-1 Nef and at least one Clusterin (Clu)-binding peptide (Clu-BP). Pharmaceutical compositions comprising these peptides alone or in synergistic combinations with other active agents in methods for treating cancers and/or infectious diseases are further provided herein.

  一种抑制细胞中外泌体释放的多肽，包括一个N端和一个C端，并包含至少一个来自HIV-1 Nef的分泌修饰区（SMR）肽和至少一个Clusterin（Clu）-结合肽（Clu-BP）。本文进一步提供了在治疗癌症和/或传染性疾病的方法中单独或与其它活性剂协同组合包含这些肽的药物组合物。
• Compositions and methods for treating SARS-CoV-2 infections
  申请人：MOREHOUSE SCHOOL OF MEDICINE

  公开号：US11180534B1

  公开（公告）日：2021-11-23

  The present application relates to methods and compositions and methods for treating viral infections, especially those caused by SARS-CoV-2. In one aspect, a method of treatment comprises administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a multipartite SARS-CoV-2-inhibiting peptide comprising a secretion modulating region (VI-SMR) peptide from HIV-1 Nef in combination with a cell-penetrating peptide (CPP) domain, a Clusterin (Clu)-binding peptide (Clu-BP) domain, a mitochondrial targeting (Mito-T) peptide domain, an anti-fusogenic (AF) peptide domain, a viral attachment inhibitor (VAI) domain or combination thereof, optionally where the SARS-CoV-2-inhibiting peptide is pegylated and/or modified with one or more hydrophobic domains.

  本申请涉及治疗病毒感染，特别是由SARS-CoV-2引起的病毒感染的方法和组合物及方法。在一个方面，一种治疗方法包括向需要这种治疗的受试者施用有效量的药物组合物，该药物组合物包含多组分 SARS-CoV-2 抑制肽，该多组分 SARS-CoV-2 抑制肽包含来自 HIV-1 Nef 的分泌调节区（VI-SMR）肽与细胞穿透肽（CPP）结构域相结合、簇蛋白（Clu）结合肽（Clu-BP）结构域、线粒体靶向（Mito-T）肽结构域、抗纺锤体（AF）肽结构域、病毒附着抑制剂（VAI）结构域或它们的组合，SARS-CoV-2 抑制肽可选地被聚乙二醇化和/或用一个或多个疏水结构域修饰。
• COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE
  申请人：Morehouse School of Medicine

  公开号：EP3554638B1

  公开（公告）日：2022-02-02
• JPH02157243A
  申请人：——

  公开号：JPH02157243A

  公开（公告）日：1990-06-18